A prospective audit of adjunctive zonisamide in an everyday clinical setting

Epilepsy and Behavior

Volumn 17, Issue 4, 2010, Pages 455-460

  Stephen, Linda J ^a   Kelly, Kevin ^a   Wilson, Elaine A ^a   Parker, Pamela ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drug; Epilepsy; Seizures; Side effects; Zonisamide

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ENZYME INDUCING AGENT; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; AGGRESSION; AGITATION; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATAXIA; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; INSOMNIA; LANGUAGE DISABILITY; LEARNING DISORDER; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEMORY DISORDER; MONOTHERAPY; MOOD DISORDER; MYALGIA; NAUSEA AND VOMITING; OUTPATIENT; PARESTHESIA; PRESCRIPTION; PROSPECTIVE STUDY; PSYCHOPATHY; SIDE EFFECT; SOMNOLENCE; THOUGHT DISORDER; TINNITUS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHEMOTHERAPY, ADJUVANT; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; MALE; MEDICAL AUDIT; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952239895     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.01.016     Document Type: Article

References (48)

1. Rock D.M., Macdonald R.L., Taylor C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989, 3:138-143.
2. Kito M., Machara M., Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996, 5:115-119.
3. +, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Clin Pharmacol 1998, 124:1277-1285.
4. 3H]Zonisamide binding in rat brain. Med J Osaka Univ 1990, 39:19-22.
5. Masuda Y., Ishizaki M., Shimizu M. Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev 1998, 4:341-346.
6. Oommen K.J., Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol 1999, 22:192-200.
7. Sobieszek G., Borowicz K.K., Kimber-Trojnar Z., et al. Zonisamide: a new antiepileptic drug. Pol J Pharmacol 2003, 55:683-689.
8. Schmidt D., Jacob R., Loiseau P., et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993, 15:67-73.
9. Faught E., Ayala R., Montouris G.G., Leppik I.E. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001, 57:1771-1779. and the Zonisamide 922 Trial Group.
10. Sackellares J.C., Ramsay R.E., Wilder B.J., Browne T.R., Shellenberger M.K. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004, 45:610-617.
11. Brodie M.J., Duncan R., Vespignani H., Solyom A., Bitenskyy V., Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005, 46:1-11.
12. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database System Rev 2005;4:CD001416. doi: 10.1002/14651858.CD001416.pub2. doi:10.1002/14651858.CD001416.pub2.
13. Yagi K., Seino M. Methodological requirement for clinical trials in refractory epilepsies: our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992, 16:79-85.
14. Kyllerman M., Ben-Menachem E. Zonisamide for progressive myoclonic epilepsy: long-term observations in seven patients. Epilepsy Res 1998, 29:109-114.
15. Newmark M.E., Dubinsky S. Zonisamide monotherapy in a multi-group clinic. Seizure 2004, 13:223-225.
16. Kothare S.V., Valencia I., Khurana D.S., Hardison H., Melvin J.J., Legido A. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004, 6:267-270.
17. Wilfong A., Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005, 64:31-34.
18. Shinnar S., Pellock J.M., Conry J.A. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009, 13:3-9.
19. You S.J., Kang H.C., Kim H.D., Lee H.S., Ko T.S. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentre experience. Brain Dev 2008, 30:287-290.
20. Yanai S., Hanai T., Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999, 21:157-161.
21. Von Elm E., Altman D., Pocock S.J., GØtzsche P.C., Vandenbroucke J.P. For the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Br Med J 2007, 335:806-808.
22. Zwarenstein M., Treweek S., Gagnier J.J., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Br Med J 2008, 337:1223-1226.
23. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
24. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
25. Leppik I.E., Willmore L.J., Homan R.W., et al. Efficacy and safety of zonisamide: results of a multicentre study. Epilepsy Res 1993, 14:165-173.
26. Marinas A., Villanueva V., Giraldez B.G., Molins A., Salas-Puig J., Serratosa J.M. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009, 11:61-66.
27. Annegers J.F., Hauser W.A., Elveback L.R. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979, 20:729-737.
28. Devinsky O. Patients with refractory seizures. N Engl J Med 1999, 340:1565-1570.
29. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
30. Cockerell O.C., Johnson A.L., Sander J.W., Shorvon S.D. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997, 38:31-46.
31. Patsalos P.N., Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:247-356.
32. Mohanraj R., Brodie M.J. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006, 13:277-282.
33. Harden C., Meador K.J., Pennell P.B., et al. Management issues for women with epilepsy: focus on pregnancy (an evidence-based review). II. Teratogenesis and perinatal outcomes. Epilepsia 2009, 50:1237-1246.
34. Meador K., Baker G., Browning N., et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
35. Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure 2004, 13(Suppl. 1):S50-55.
36. Stephen L.J., Sills G.J., Brodie M.J. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000, 41:977-980.
37. Mohanraj R., Parker P., Stephen L.J., Brodie M.J. Levetiracetam in refractory epilepsy: a prospective observational study. Seizure 2005, 14:23-27.
38. Marescaux C., Hirsch E., Finck S., et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990, 31:768-777.
39. Wakai S., Ito N., Ueda D., Chiba S. Landau-Kleffner syndrome and sulthiamine. Neuropediatrics 1997, 28:135-136.
40. Appleton R., Hughes A., Beirne M., Acomb B. Vigabatrin in the Landau-Kleffner syndrome. Dev Med Child Neurol 1993, 35:457-459.
41. Kossoff E.H., Boatman D., Freeman J.M. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav 2003, 4:571-575.
42. Park S.-P., Hwang Y.-H., Lee H.-W., Suh C.-K., Kwon S.-H., Lee B.-I. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008, 12:102-108.
43. Miyamoto T., Kohsaka M., Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000, 9:65-70.
44. Arif H., Buchsbaum R., Weintraub D., et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007, 68:1701-1709.
45. Frampton J.E., Scott L.J. Zonisamide. A review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005, 19:347-367.
46. Neuman M.G., Shear N.H., Malkiewicz I.M., Kessas M., Lee A.W., Cohen L. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol 2008, 17:1045-1051.
47. Isojärvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., Myllalä V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996, 39:579-584.
48. Wellmer J., Wellmer S., Bauer J. The impact of zonisamide on weight: a clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009, 119:233-238.